Finanzen von Carlsmed, Inc. (CARL)CARLCarlsmed, Inc.

Evaluating the bottom line, Carlsmed, Inc. maintains a gross margin of 76.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -58.27%, while the net margin is -55.49%. These profitability ratios, combined with a Return on Equity (ROE) of -6196.93%, provide a clear picture of how effectively CARL converts its operational activities into shareholder value.

In the context of the broader market, CARL competes directly with industry leaders such as CINT and RMNI. With a market capitalization of $390.98M, it holds a significant position in the sector. When comparing efficiency, CARL's gross margin of 76.78% stands against CINT's 31.09% and RMNI's 60.95%. Such benchmarking helps identify whether Carlsmed, Inc. is trading at a premium or discount relative to its financial performance.

Carlsmed's revenue has shown significant growth, with Q2 2026 revenue at $18.9 million, a 57% increase year-over-year. The gross margin improved to 76.8%, reflecting effective cost control. However, the company reported a net loss of $10.5 million in Q2 2026, up from $6.8 million in Q2 2025, indicating challenges in achieving profitability despite revenue growth.